TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
15 mai 2023 02h00 HE
|
TILT Biotherapeutics Oy
HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the first patient has been...
Global Oncolytic Virus Therapy Clinical Pipeline Insight 2028
20 mars 2023 03h21 HE
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview: Global Oncolytic Virus Immunotherapy Therapy Market...
Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
15 nov. 2022 16h00 HE
|
Virogin Biotech
VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study...
Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers
08 sept. 2022 15h01 HE
|
Virogin Biotech Canada
VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced...
Global Oncolytic Virus Therapy Market 2026 Companies Clinical Trials Insight
02 nov. 2020 03h37 HE
|
KuicK Research
DELHI, India, Nov. 02, 2020 (GLOBE NEWSWIRE) -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights: Global Oncolytic Virus...
Global Oncolytic Virus Immunotherapy Market A US$ 700 Million Opportunity By 2026
08 oct. 2020 13h19 HE
|
KuicK Research
DELHI, India, Oct. 08, 2020 (GLOBE NEWSWIRE) -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights: Global Oncolytic Virus...
Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials
28 sept. 2020 09h00 HE
|
Imvaq Therapeutics
NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Imvaq Therapeutics Corp., an innovative cancer immunotherapy company founded by world-leading researchers at Memorial Sloan Kettering Cancer Center...